 VANCOUVER, British Columbia--BUSINESS WIRE--Zymeworks Inc. NYSE: ZYME, a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the selection of three abstracts for presentation at the American Society of Clinical Oncology ASCO Gastrointestinal Cancers Symposium, taking place virtually on January 15 17, 2021. The presentations highlight updated clinical data for the HER2targeted bispecific antibody, zanidatamab, in HER2expressing gastroeso 